Lilly Ends Trial Of BACE Inhibitor For Alzheimer’s, But Says Class-Wide Safety Effect Unlikely
This article was originally published in The Pink Sheet Daily
Executive Summary
With the termination of a Phase II trial of LY2887621, Merck’s MK-8931 leads the race to become the first BACE inhibitor approved for Alzheimer’s, although four other companies have similar candidates in earlier stages of development. Lilly says it may continue to pursue BACE inhibition in Alzheimer’s.
You may also be interested in...
AZ, Lilly's BACE Inhibitor Clears Safety Hurdle And Raises Class Hopes
All clear from monitoring board means firms will roll into the Phase III portion of the AMARANTH trial.
Lilly Poised To Lead In Alzheimer’s, But Success Depends On Solanezumab
Lilly's comprehensive R&D initiative to lead in Alzheimer’s disease includes seven drugs in or nearing the clinic, with an eye on combinations. But until data from a third Phase III trial testing solanezumab read out in late 2016/early 2017, investors remain skeptical.
Regulatory Briefs: Ebola Trials Protocol, AstraZeneca Resubmits Iressa
FDA officials explain why randomized clinical trials of Ebola products are necessary and the Senate passes Ebola priority review voucher bill. Lilly/AstraZeneca start Alzeimer’s trial, Incyte gains new approval for Jakafi, Sunovion files for new use of Aptiom and AstraZeneca resubmits its once withdrawn lung cancer drug Iressa.